Adherium ’s Smartinhaler Gets FDA Nod for AstraZeneca Inhalers
https://www.tipranks.com/news/company-announcements/adheriums-smartinhaler-gets-fda-nod-for-astrazeneca-inhalers?utm_source=biztoc.com&utm_medium=referral (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2024 Category: Consumer Health News Source Type: news
AstraZeneca CEO set to earn £18.7 million after shareholder backing
More than 60% of shareholders backed the decision to raise Pascal Soriot’s pay packet, solidifying his position as the highest earning FTSE 100 boss. The chief executive of pharmaceutical giant AstraZeneca could earn up to £18.7 million (€21.9 million) this year after shareholders approved a…#pascalsoriots #ftse #astrazeneca #rajivjain #gqgpartners #sundaytimes #glasslewis #supportersofsoriot #frenchman #elilillyco (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2024 Category: Consumer Health News Source Type: news
Health Care Roundup: Market Talk
AstraZeneca, Alpine Immune Sciences and more in the latest Market Talks covering the Health Care sector.#astrazeneca #alpineimmunesciences #markettalks #healthcare (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2024 Category: Consumer Health News Source Type: news
Fasenra Approved for Treatment of Children Aged 6 to 11 with Severe Asthma
WILMINGTON, Del.--(BUSINESS WIRE) April 11, 2024 --AstraZeneca’s Fasenra® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 11, 2024 Category: Drugs & Pharmacology Source Type: news
FDA Expands Approval of Severe Asthma Drug
(MedPage Today) -- The FDA expanded the approval of benralizumab (Fasenra) to include treatment of younger kids with uncontrolled severe asthma with an eosinophilic phenotype, AstraZeneca announced on Thursday.
Previously approved for individuals... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - April 11, 2024 Category: Allergy & Immunology Source Type: news
Why Is AstraZeneca Stock Trading Higher Today?
Thursday, AstraZeneca Plc AZN raised its annualized dividend for 2024 by $0.20 to $3.10 per share, underlining the company’s confidence in its performance and cash generation. The company said the 7% increase takes into account other capital allocation priorities and previously announced…#astrazenecaplcazn #micheldemaré #astrazeneca #highlightsdecadelong #pascalsoriots #glasslewis #sophielundyates #hargreaveslansdown #astra #eps (Source: Reuters: Health)
Source: Reuters: Health - April 11, 2024 Category: Consumer Health News Source Type: news
AstraZeneca, Daiichi Drug gets broad tumor approval in US
Enhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread throughout the body, marking a breakthrough in cancer treatment. It's the first antibody drug conjugate with such wide clearance, offering new hope for patients with limited treatment options. AstraZeneca anticipates further growth opportunities. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 8, 2024 Category: Pharmaceuticals Source Type: news
AstraZeneca, Daiichi Drug Gets Broad Tumor Approval in US
(Source: Reuters: Health)
Source: Reuters: Health - April 8, 2024 Category: Consumer Health News Source Type: news
Enhertu Approved in the US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors
April 6, 2024 -- AstraZeneca and Daiichi Sankyo ' s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 6, 2024 Category: Drugs & Pharmacology Source Type: news
AstraZeneca's Imfinzi Improves Survival in Late-stage Lung Cancer Trial AstraZeneca's Imfinzi Improves Survival in Late-stage Lung Cancer Trial
AstraZeneca said on Friday its blockbuster cancer drug Imfinzi helped improve survival in patients in the early stages of an aggressive type of lung cancer, making it the...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 5, 2024 Category: Allergy & Immunology Tags: Hematology-Oncology Source Type: news
Factor D Inhibitor Wins Approval for PNH With Extravascular Hemolysis
(MedPage Today) -- The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH), AstraZeneca announced.
The approval specifies use... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 4, 2024 Category: Hematology Source Type: news
Scientists Find New Genetic Variants for Obesity
Researchers believe they have discovered a new biological mechanism for obesity, pointing to rare variants on two genes that dramatically increase the risk of carrying excess weight.
Research published in the journal Nature Genetics on Thursday points to variants that raise the chance of being obese by as much as six times. Unlike other known variants that affect weight gain in children, these only appear to play a role in adults.
[time-brightcove not-tgx=”true”]
Unraveling obesity’s mechanisms could help scientists develop new drugs, or tailor existing ones, for a condition that now affects ...
Source: TIME: Health - April 4, 2024 Category: Consumer Health News Authors: Ashleigh Furlong/Bloomberg Tags: Uncategorized healthscienceclimate wire Source Type: news
Datopotamab Deruxtecan Biologics License Application Accepted in the US for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer
2 April 2024 -- AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 2, 2024 Category: Drugs & Pharmacology Source Type: news
Brainomix touts e-Lung software clinical study results
U.K. AI software developer Brainomix highlighted a study that shows its e-Lung automated CT processing algorithm can stratify patients at risk of idiopathic pulmonary fibrosis (IPF).The study was an analysis of a completed phase II clinical trial by AstraZeneca of the company’s tralokinumab treatment in patients with idiopathic pulmonary fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool.e-Lung is powered by what is called the weighted reticulovascular score (WRVS), a biomarker that incorporates reticular opacities and vascular structures in assessments of the lung, Brainomix sai...
Source: AuntMinnie.com Headlines - March 27, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock
Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.#fusion #azn (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2024 Category: Consumer Health News Source Type: news